ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: Tyrosine kinase inhibitors (TKIs, of which the first was imatinib mesylate) act by blocking the ATP binding site of BCR-ABL, and are key drugs for the treatment of CML and other malignancies such as gastrointestinal stromal tumours whose growth depends on the activity of specific kinases [77].